Prostate cancer Posts on Medivizor
Navigation Menu

Prostate cancer Posts on Medivizor

Evaluating the benefits of radiotherapy dose escalation and the addition of short-term or long-term androgen deprivation therapy in men with localized prostate cancer.

Evaluating the benefits of radiotherapy dose escalation and the addition of short-term or long-term androgen deprivation therapy in men with localized prostate cancer.

Posted by on Sep 27, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the benefits of radiation therapy (RT) dose escalation and the addition of short-term (ST) or long-term (LT) androgen deprivation therapy (ADT) to RT in men with localized prostate cancer (PCa). The data showed that the addition of ST or LT-ADT to RT improved survival without metastasis in these patients,...

Read More

Evaluating the long-term outcomes of radiotherapy added to standard therapy for men with metastatic prostate cancer.

Evaluating the long-term outcomes of radiotherapy added to standard therapy for men with metastatic prostate cancer.

Posted by on Sep 18, 2022 in Prostate cancer | 0 comments

In a nutshell The study investigated whether radiotherapy (RT) addedd to standard of care (SOC) treatment would be beneficial for men with metastatic (spread) prostate cancer (mPC). The study showed that adding RT to SOC improved the survival of men with low burden (defined as fewer than 10 lesions, no greater than 3cm in diameter) mPC. Some...

Read More

Evaluating the bone mineral density screening rates and their association with fracture rates among older men with prostate cancer receiving androgen deprivation therapy.

Evaluating the bone mineral density screening rates and their association with fracture rates among older men with prostate cancer receiving androgen deprivation therapy.

Posted by on Sep 17, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the bone mineral density (BMD) screening rates and their association with fracture rates among older men with prostate cancer (PC) receiving androgen deprivation therapy (ADT). The data showed that BMD screening is associated with a lower major fracture risk in these patients. Some background Prostate...

Read More

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Posted by on Sep 1, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...

Read More

Evaluating depression, anxiety, and patterns of mental health care in patients with prostate cancer receiving hormone therapy

Evaluating depression, anxiety, and patterns of mental health care in patients with prostate cancer receiving hormone therapy

Posted by on Sep 1, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated depression, anxiety, and patterns of mental health care in patients with prostate cancer receiving hormonal therapy such as androgen deprivation therapy (ADT). The data showed that almost half of the patients with prostate cancer receiving ADT diagnosed with depression do not receive a documented mental health...

Read More

Evaluating the benefits of adding androgen deprivation therapy to radiation therapy and extending its duration in men with localized prostate cancer.

Evaluating the benefits of adding androgen deprivation therapy to radiation therapy and extending its duration in men with localized prostate cancer.

Posted by on Aug 14, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the benefits of adding androgen deprivation therapy (ADT) to radiation therapy (RT) and the benefit of extending the duration of ADT in men with localized prostate cancer (PCa). The data showed that the addition of ADT to RT and extending the duration of ADT administered after RT significantly improved the survival...

Read More

Evaluating the effects of olaparib on pain and the health-related quality of life in patients with metastatic castration-resistant prostate cancer.

Evaluating the effects of olaparib on pain and the health-related quality of life in patients with metastatic castration-resistant prostate cancer.

Posted by on Aug 8, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effects of olaparib (Lynparza) on pain and the health-related quality of life (HR-QoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) with mutations (genetic abnormalities) in DNA repair genes. The data showed that treatment with olaparib was associated with a reduction in pain and...

Read More

Evaluating the effectiveness and safety of darolutamide in combination with androgen deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer.

Evaluating the effectiveness and safety of darolutamide in combination with androgen deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer.

Posted by on Jul 16, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) and docetaxel (Taxotere) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that darolutamide in combination with ADT and docetaxel significantly improved the overall...

Read More

Evaluating the effectiveness and safety of 225Ac-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of 225Ac-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer.

Posted by on Jun 26, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of actinium-225 [225Ac]-PSMA-617 (225AcPSMA) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that 225AcPSMA was effective with manageable side effects for these patients. Some background Prostate cancer (PC) often grows in...

Read More

Reviewing chemotherapy and hormonal therapy before prostate surgery in patients with prostate cancer

Reviewing chemotherapy and hormonal therapy before prostate surgery in patients with prostate cancer

Posted by on Jun 14, 2022 in Prostate cancer | 0 comments

In a nutshell The review investigated the effects of neoadjuvant chemo-hormonal therapy (NCHT; chemotherapy and hormonal therapy before surgery) in patients with prostate cancer (PCa). The results showed that compared to patients who received prostate surgery alone, NCHT before prostate surgery improved the oncological outcomes of these...

Read More

Comparing Retzius-sparing and conventional robot-assisted radical prostatectomy for men with localized prostate cancer

Comparing Retzius-sparing and conventional robot-assisted radical prostatectomy for men with localized prostate cancer

Posted by on Jun 5, 2022 in Prostate cancer | 0 comments

In a nutshell This review compared the outcomes of 2 techniques for robotic-assisted radical prostatectomy (RARP; complete removal of the prostate gland using robotic arms): Retzius-sparing (RS)-RARP and conventional (C)-RARP in patients with localized prostate cancer (PCa). The analysis showed that RS-RARP was associated with improved urinary...

Read More

Evaluating the effectiveness and safety of adding abiraterone acetate and prednisolone with or without enzalutamide to androgen-deprivation therapy in patients with high-risk non-metastatic prostate cancer.

Evaluating the effectiveness and safety of adding abiraterone acetate and prednisolone with or without enzalutamide to androgen-deprivation therapy in patients with high-risk non-metastatic prostate cancer.

Posted by on May 31, 2022 in Prostate cancer | 0 comments

In a nutshell The study evaluated the effectiveness and safety outcomes of adding abiraterone acetate (AA; Zytiga) and prednisolone (P; Deltasone) with or without enzalutamide (Xtandi) to androgen-deprivation therapy (ADT) in patients with high-risk non-metastatic prostate cancer (PC). The data showed that AAP added to ADT significantly improved survival...

Read More